Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome
Author:
Publisher
Wiley
Subject
Transplantation
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1399-0012.2005.00334.x/fullpdf
Reference14 articles.
1. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report
2. Thrombotic Microangiopathies
3. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
4. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab
5. von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura;Journal of Thrombosis and Haemostasis;2022-10
2. Rituximab in kidney disease and transplant;Animal Models and Experimental Medicine;2019-03-26
3. Microangiopathie thrombotique et cancer;Néphrologie & Thérapeutique;2017-11
4. De Novo and Recurrence of Renal Disease;Kidney Transplantation, Bioengineering and Regeneration;2017
5. Thrombotic Microangiopathy, Cancer, and Cancer Drugs;American Journal of Kidney Diseases;2015-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3